Effect of oxidative stress on endothelium in patients with heart failure and type 2 diabetes ­mellitus

Abstract

Aim. To estimate the severity of endothelial dysfunction and effects of nitric oxide, thiol status and cystatin on the progression of chronic heart failure and chronic heart failure in type 2 diabetes mellitus.

Methods. 80 patients (men and women) with chronic heart failure were included. All patients were divided into two groups: the first group — 39 patients with chronic heart failure, the second — 41 people with chronic heart failure and type 2 diabetes mellitus. The control group consists of 20 healthy donors. To obtain statistically significant differences with the control group the minimum sample size for observations was determined based on the target variance of a small sample (n=10). The lipid profile and carbohydrate metabolism, endothelin-1, cystatin, nitric oxide were evaluated. Statistical processing was performed using Microsoft Office Excel and IBM SPSS Statistics 20 software.

Results. Changes in lipid metabolism were found in both groups, while an increase in carbohydrate metabolism was observed in patients with chronic heart failure with type 2 diabetes mellitus. Under conditions of oxidative stress in patients with chronic heart failure, a decrease in the content of thiol status and an increase in the amount of nitric oxide in the blood serum were recorded. The endothelin-1 level was elevated, particularly in the second group, which indicates a more serious endothelial dysfunction with increased glucose content in patients with chronic heart failure.

Conclusion. The level of cystatin C as an atherogenic risk factor was equally increased in the studied patients, possibly it affected by the rate of disease progression; feasible to use these markers to detect the progression of chronic heart failure in the early stages.

Keywords

endothelin-1 / nitric oxide / cystatin C / thiol status / chronic heart failure / endothelial dysfunction / oxidative stress

References

[1] Zakhidova K.Kh. Chro­nic heart failure and anemia: questions on diagnosis and treatment. Abstract of dissertation for the degree of Doctor of Medical Sciences. Baku: Azerbaijan medical university. 2018; 46 р. (In Russ.)

[2] Захидова К.Х. Хроническая сердечная недостаточность и анемия: вопросы диагностики и лечения. Автореф. дисс. … докт. мед. наук. Баку: Азербайджанский мед. ун-т. 2018; 46 с.

[3] Belenkov Yu.N., Privalova E.V., Danilogorskaya Yu.A. et al. Oxidative stress in chro­nic heart failure. Opportunities of pharmacological correction. Kardiologiya i serdechno-sosudistaya khirurgiya. 2009; (1): 4–9. (In Russ.)

[4] Беленков Ю.Н., Привалова Е.В., Данилогорская Ю.А. и др. Оксидативный стресс при хронической сердечной недостаточности. Возможности фармакологической коррекции. Кардиол. и сердечно-сосудист. хир. 2009; (1): 4–9.

[5] Mel’nikova Yu.S., Makarova T.P. Endothelial dysfunction as a key link of chronic diseases pathogenesis. Kazanskiy meditsinskiy zhurnal. 2015; 96 (4): 659–665. (In Russ.)

[6] Мельникова Ю.С., Макарова Т.П. Эндотелиальная дисфункция как центральное звено патогенеза хронических болезней. Казанский мед. ж. 2015; 96 (4): 659–665. DOI: 10.17750/KMJ2015-659.

[7] Bernardi F.C., Vuolo F., Petronilho F. et al. Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in the plasma and placentae from preeclamptic patients. An. Acad. Bras. Ciênc. 2015; 87 (2): 713–719. DOI: 10.1590/0001-3765201520140069.

[8] Higashi Y., Noma K., Yoshizumi M., Kihara Y. Endothelial function and oxidative stress in cardiovascular di­seases. Circulation J. 2009; 3: 411–418. DOI: 10.1253/circj.cj-08-1102.

[9] Voronina L.P. Genetic, biochemical and functio­nal markers of condition of vasoregulating function of endothelium. Sibirskiy meditsinskiy zhurnal. 2011; (3): 29–31. (In Russ.)

[10] Воронина Л.П. Генетические, биохимические и функциональные маркёры состояния вазорегулирующей функции эндотелия. Сибирский мед. ж. 2011; (3): 29–31.

[11] Lakin G.F. Biometriya. (Biometrics.) 4th ed. Moscow: Vysshaya shkola. 1990; 309–310. (In Russ.)

[12] Лакин Г.Ф. Биометрия. 4-е изд., испр. и доп. М.: Высшая школа. 1990; 309–310.

[13] Pizov N.A., Pizov A.V., Skachkova O.A., Pizova N.V. Endothelial function in normal and pathological conditions. Meditsinskiy sovet. 2019; 6: 154–159. (In Russ.)

[14] Пизов Н.А., Пизов А.В., Скачкова О.А., Пизова Н.В. Эндотелиальная функция в норме и при патологии. Мед. совет. 2019; 6: 154–159. DOI: 10.21518/2079-701X-2019-6-154-159.

[15] Statsenko M.E., Turkina S.V., Belenkova S.V. et al. Effects of mildronate, as a part of combined heart failure therapy, on carbohydrate and lipid metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus. Rossiyskiy kardiologicheskiy zhurnal. 2010; (2): 45–51. (In Russ.)

[16] Стаценко М.Е., Туркина С.В., Беленкова С.В. и др. Влияние милдроната в составе комбинированной терапии хронической сердечной недостаточности у больных сахарным диабетом 2 типа на углеводный, липидный обмен и показатели оксидативного стресса. Рос. кардиол. ж. 2010; (2): 45–51. . DOI: 10.15829/1560-4071-2010-2-45-51.

[17] Eleuteri E., Magno F., Gnemmi I. et al. Role of oxi­dative and nitrosative stress biomarkers in chronic heart failure. Front. Biosci. (Landmark Ed.). 2009; 1 (14): 2230–2237. DOI: 10.2741/3375.

[18] Akbasheva O.E., Ageeva T.S., D’yakov D.A. The activity of the antioxidant system in blood plasma in type II diabetes mellitus. Molodoy uchyonyy. 2018; (35): 21–23. (In Russ.)

[19] Акбашева О.Е., Агеева Т.С., Дьяков Д.А. Активность антиоксидантной системы в плазме крови при сахарном диабете II типа. Молодой учёный. 2018; (35): 21–23.

[20] Koning A.M., Meijers W.C., Pasch A. et al. Serum free thiols in chronic heart failure. Pharmacol. Res. 2016; 111: 452–458. DOI: 10.1016/j.phrs.2016.06.027.

[21] Bessonova I.N. Endothelial function and vasoactive factors in adolescents with arterial hypertension and hyperuricemia. Sovremennaya pediatriya. 2014; (5): 53–58. (In Russ.)

[22] Бессонова И.Н. Эндотелиальная функция и вазоактивные факторы у подростков с артериальной гипертензией и гиперурикемией. Соврем. педиатрия. 2014; (5): 53–58.

[23] Kosheleva N.A., Rebrov A.P. Endothelial dysfunction in patients with chronic heart failure. Vestnik sovremennoy klinicheskoy meditsiny. 2009; 2 (1): 9–14. (In Russ.)

[24] Кошелева Н.А., Ребров А.П. Дисфункция эндотелия у больных хронической сердечной недостаточностью. Вестн. соврем. клин. мед. 2009; 2 (1): 9–14.

[25] Panasenko V.G., Mironenko S.P., Karas’kov A.M., Pustovetova M.G. Markers of endothelial dysfunction in dynamics of myocardial ischemia at young persons. Meditsina i obrazovanie v Sibiri. 2011; 6. http://ngmu.ru/cozo/mos/article/pdf.php?id=543 (access date: 21.09.2019). (In Russ.)

[26] Панасенко В.Г., Мироненко С.П., Караськов А.М., Пустоветова М.Г. Маркёры эндотелиальной дисфункции в динамике ишемической болезни сердца у лиц молодого возраста. Медицина и образование в Сибири. 2011; 6. http://ngmu.ru/cozo/mos/article/pdf.php?id=543 (дата обращения: 21.09.2019).

[27] Gerasimchuk P.A., Kisil’ P.V., Vlasenko V.G., Pavlyshin A.V. Endothelial dysfunction indicators in patients with diabetic foot syndrome. Vestnik RAMN. 2014; (5–6): 107–110. (In Russ.)

[28] Герасимчук П.А., Кисиль П.В., Власенко В.Г., Павлышин А.В. Показатели эндотелиальной дисфункции у больных с синдромом диабетической стопы. Вестн. РАМН, 2014; (5–6): 107–110. DOI: 10.15690/vramn.v69i5-6.1053.

[29] Gu F.F., Lü S.Z., Chen Y.D. et al. Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. Chin. Med. J. (Engl.). 2009; 122 (23): 2820. DOI: 10.3760/cma.j.issn.0366-6999.2009.23.004.

[30] Angelidis C., Deftereos S., Giannopoulos G. et al. Cystatin C: an emerging biomarker in cardiovascular di­sease. Curr. Top. Med. Chem. 2013; 13 (2): 164–179. DOI: 10.2174/1568026611313020006.

[31] Serik S.A., Ovrakh T.G. Association between cystatin C and major adverse cardiac events in patients with ischemic heart disease and type 2 diabetes mellitus after acute coronary syndrome. Zaporozhskiy meditsinskiy zhurnal. 2019; (3): 302–307. (In Russ.)

[32] Серик С.А., Оврах Т.Г. Цистатин С и его связь с возникновением сердечно-сосудистых событий у больных ишемической болезнью сердца в сочетании с сахарным диабетом 2 типа после перенесённого острого коронарного синдрома. Запорожский мед. ж. 2019; (3): 302–307. DOI: 10.14739/2310-1210.2019.3.168962.

[33] Chung Y.K., Lee Y.J., Kim K.W. et al. Serum cystatin C is associated with subclinical atherosclerosis in patients with type 2 diabetes: A retrospective study. Diab. Vasc. Dis. Res. 2018; 15 (1): 24–30. DOI: 10.1177/1479164117738156.

[34] Kobayashi T., Yokokawa H., Fujibayashi K. et al. Association between high cystatin C levels and carotid athe­rosclerosis. World J. Cardiol. 2017; 9 (2): 174–181. DOI: 10.4330/wjc.v9.i2.174.

RIGHTS & PERMISSIONS

Mammadova F.I.